$3.05
▼ -4.7% Today
as of Aug 5, 16:46 ET
Last 30 days
Recent Press Releases & News
Anavex Announces Board Refresh as It Seeks to Strengthen Governance and Advance Drug Pipeline
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Anavex Life Sciences Reports Preliminary Q2 2026 Results and Advances FDA Strategy for Blarcamesine
Overview
52-week range
$2.56
$14
4% of range
Avg surprise (last 2)
-2.2%
Avg reaction (last 1)
-5.0%
0% positive
Latest IV / EM
75%
EM ±12.5% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed Dec 31, 2025 | Dec 2025 | $-0.06 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.16 | $-0.13 | -23.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.13 | $-0.16 | +18.8% | — | -5.0% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-0.14 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.14 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.13 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.11 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.14 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.17 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.08 | -$0.16 | +50.0% |
Financials
Income statement (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | — | $-14M | $-13M | $-14M | — | $-15M | $-13M |
| Net income | $-6M | — | $-13M | $-11M | $-12M | — | $-12M | $-11M |
| EPS (diluted) | $-0.06 | — | $-0.16 | $-0.13 | $-0.14 | — | $-0.14 | $-0.13 |
Balance sheet (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $132M | $103M | $101M | $116M | $121M | $132M | $139M | $139M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | — | — | — | — | — | — | — | — |
| Total assets | $133M | $104M | $102M | $117M | $124M | $136M | $142M | $145M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $6M | $9M | $11M | $17M | $13M | $15M | $12M | $10M |
| Total equity | $127M | $95M | $91M | $100M | $111M | $120M | $130M | $135M |